Back to Search Start Over

CD133 antibody targeted delivery of gold nanostars loading IR820 and docetaxel for multimodal imaging and near-infrared photodynamic/photothermal/chemotherapy against castration resistant prostate cancer.

Authors :
Tan H
Hou N
Liu Y
Liu B
Cao W
Zheng D
Li W
Liu Y
Xu B
Wang Z
Cui D
Source :
Nanomedicine : nanotechnology, biology, and medicine [Nanomedicine] 2020 Jul; Vol. 27, pp. 102192. Date of Electronic Publication: 2020 Mar 27.
Publication Year :
2020

Abstract

Due to the lack of effective strategies on the treatment of castration resistant prostate cancer (CRPC), we established a multifunctional nanoplatform (GNS@IR820/DTX-CD133) for the synergistic photothermal therapy (PTT)/photodynamic therapy (PDT)/chemotherapy (CT) under the monitoring of multimodal near-infrared (NIR) fluorescence/photoacoustic (PA) imaging. Benefiting from the guided effect of CD133 antibody, GNS@IR820/DTX-CD133 can targetedly deliver the loaded drug to the tumor tissues, which can further contribute to the combined therapeutic effect. Our experimental results prove that the bio-distribution of GNS@IR820/DTX-CD133 can be monitored with NIR fluorescence and PA imaging. In addition, the application of GNS@IR820/DTX-CD133 for in vitro and in vivo therapy achieves the excellent antitumor effects of the synergistic PTT/PDT/CT strategies under the NIR-light irradiation. Therefore, as a multifunctional nanoplatform integrating the PTT/PDT/CT strategies with tumor multimodal imaging or drug tracing, GNS@IR820/DTX-CD133 has the great potential for clinical applications in the antitumor therapy of CRPC.<br /> (Copyright © 2020 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1549-9642
Volume :
27
Database :
MEDLINE
Journal :
Nanomedicine : nanotechnology, biology, and medicine
Publication Type :
Academic Journal
Accession number :
32229215
Full Text :
https://doi.org/10.1016/j.nano.2020.102192